Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Tetra-Pharm

More Like This

PR Newswire associated0

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the Discovery of Novel Drug Candidates Targeting the Endocannabinoid System

PR Newswire associated0

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

PR Newswire associated0

Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances

First product based on LTS Sorrel™ wearable drug delivery platform launched in the US

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating an advanced solution to Pain Research

ACCESSWIRE logo

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD